Literature DB >> 31384105

Pulmonary Arterial Hypertension and Therapeutic Interventions.

Nader B Ishak Gabra1, Omar Mahmoud1, Oki Ishikawa1, Varun Shah1, Erica Altshul1, Maly Oron1, Bushra Mina1.   

Abstract

Pulmonary hypertension is an uncommon disease that carries a significant morbidity and mortality. Pulmonary arterial hypertension is a subtype of pulmonary hypertension that describes a group of disease entities that lead to an elevation in precapillary pulmonary artery pressure. Despite advances in the diagnosis and treatment of pulmonary arterial hypertension, it remains a difficult disease to recognize and manage. In this review article, we will discuss the definition and diagnosis of pulmonary arterial hypertension. Additionally, we will discuss the ever-expanding management options, their mechanisms and strategies, including combination therapy and the most recent advances and future directions.

Entities:  

Keywords:  calcium channel blockers; combination therapy; endothelin receptor antagonists; phosphodiesterase-5 inhibitor; prostacyclin analog; pulmonary arterial hypertension; pulmonary hypertension

Year:  2019        PMID: 31384105      PMCID: PMC6679959          DOI: 10.1055/s-0039-1692452

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  93 in total

1.  Optimal diuretic therapy for heart failure.

Authors:  J N Cohn
Journal:  Am J Med       Date:  2001-11       Impact factor: 4.965

Review 2.  Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research.

Authors:  K R Minter; M T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2001-12-01       Impact factor: 21.405

3.  Genetic clues to the cause of primary pulmonary hypertension.

Authors:  J Loscalzo
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

4.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.

Authors:  R M Tuder; C D Cool; M W Geraci; J Wang; S H Abman; L Wright; D Badesch; N F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  1999-06       Impact factor: 21.405

5.  Bosentan therapy for pulmonary arterial hypertension.

Authors:  Lewis J Rubin; David B Badesch; Robyn J Barst; Nazzareno Galie; Carol M Black; Anne Keogh; Tomas Pulido; Adaani Frost; Sebastien Roux; Isabelle Leconte; Michael Landzberg; Gerald Simonneau
Journal:  N Engl J Med       Date:  2002-03-21       Impact factor: 91.245

6.  Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension.

Authors:  D H Roberts; J J Lepore; A Maroo; M J Semigran; L C Ginns
Journal:  Chest       Date:  2001-11       Impact factor: 9.410

7.  Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

Authors:  D B Badesch; V F Tapson; M D McGoon; B H Brundage; L J Rubin; F M Wigley; S Rich; R J Barst; P S Barrett; K M Kral; M M Jöbsis; J E Loyd; S Murali; A Frost; R Girgis; R C Bourge; D D Ralph; C G Elliott; N S Hill; D Langleben; R J Schilz; V V McLaughlin; I M Robbins; B M Groves; S Shapiro; T A Medsger
Journal:  Ann Intern Med       Date:  2000-03-21       Impact factor: 25.391

8.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

Authors:  R N Channick; G Simonneau; O Sitbon; I M Robbins; A Frost; V F Tapson; D B Badesch; S Roux; M Rainisio; F Bodin; L J Rubin
Journal:  Lancet       Date:  2001-10-06       Impact factor: 79.321

9.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Authors:  Gerald Simonneau; Robyn J Barst; Nazzareno Galie; Robert Naeije; Stuart Rich; Robert C Bourge; Anne Keogh; Ronald Oudiz; Adaani Frost; Shelmer D Blackburn; James W Crow; Lewis J Rubin
Journal:  Am J Respir Crit Care Med       Date:  2002-03-15       Impact factor: 21.405

10.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.

Authors:  S Eddahibi; M Humbert; E Fadel; B Raffestin; M Darmon; F Capron; G Simonneau; P Dartevelle; M Hamon; S Adnot
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

View more
  2 in total

Review 1.  Therapeutic Implications for PDE2 and cGMP/cAMP Mediated Crosstalk in Cardiovascular Diseases.

Authors:  Mirna S Sadek; Eleder Cachorro; Ali El-Armouche; Susanne Kämmerer
Journal:  Int J Mol Sci       Date:  2020-10-10       Impact factor: 5.923

2.  CircIMPACT: An R Package to Explore Circular RNA Impact on Gene Expression and Pathways.

Authors:  Alessia Buratin; Enrico Gaffo; Anna Dal Molin; Stefania Bortoluzzi
Journal:  Genes (Basel)       Date:  2021-07-06       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.